Diederich Healthcare crunched the data from medical malpractice payouts in 2011 and found that 58% of payments went to women and New York state had by far the highest total payments at $677 million. According to the chart, the total medical malpractice payments were virtually the same as in 2010. Physicians Practice notes that just because the amount of total payouts in a particular state may be among the highest, that doesn’t mean a doctor should expect to pay the highest premiums, and vice versa.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A few full-time employees and lots of outsourced support vendors may be the model of the future for biotech companies, based on Shire’s purchase of FerroKin Bio Sciences. This model works for venture companies because it can shorten the time to proof of concept and for pharma companies because they can build the pipeline without acquiring duplicate research infrastructure.
Lawmakers are exploring charges that small drug-wholesale companies are setting up pharmacies to manipulate the price of cancer drugs that are in short supply. House investigators say that in the case of fluorouracil, the drug was initially sold for $6.77 a vial to one supplier and then sold to another company for $69 a vial.
iMedicalApps gives a thumbs up to the first sterile iPad sleeve released by Echo Medical in partnership with Protek Medical. The Class 2 medical device fits snugly around the iPad and is like “inserting an X-ray jacket inside a sterile sleeve,” according to Dr. Felasfa Wodajo’s review.
In a Comment on a new study of cobalt-chromium everolimus eluting (CoCr-EES) stents published in The Lancet, two doctors say that CoCr-EES should be the standard for future design improvements. The meta-analysis of 49 randomized trials comparing different stents showed that Xience and Promus stents have a significantly lower rate of stent thrombosis than bare-metal stents and other drug-eluting stents, both initially and long-term.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
[Image from infographic from Diederich Healthcare]
